EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Ex Vivo LRRK2 Activation in Asian G2385R and R1628P Variant Carriers and Idiopathic Parkinson's Disease

Tzi Shin Toh iD, Lei Cheng Lit iD, Shen-Yang Lim iD, Jia Wei Hor iD, Choey Yee Lew iD, Anis Nadhirah Khairul Anuar iD, Yi Wen Tay iD, Kirsten Black, Jia Lun Lim iD, Jannah Zulkefli iD, Kai Shi Lim iD, Hans Xing Ding iD und 6 weitere

Movement Disorders · 2026-07 · 41 (7) · 1750-1761

DOI: 10.1002/mds.70314 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 20.04.2026. Verfasst von Tzi Shin Toh und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Parkinson Disease. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Michael J. Fox Foundation for Parkinson's Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Leucine‐rich repeat kinase 2 (LRRK2) kinase inhibition is a promising therapeutic strategy for Parkinson's disease (PD), but the functional impact of Asian‐prevalent LRRK2 p.G2385R and p.R1628P variants remains unclear. Robust patient stratification and target engagement markers are needed for global LRRK2‐targeted trials.

Objective

The aim of this study was to characterize ex vivo LRRK2 activation status and its clinical correlates in patients with PD carrying LRRK2 p.G2385R and/or p.R1628P variants and in patients with idiopathic PD (iPD).

Methods

We recruited 242 participants: patients with PD carrying LRRK2 p.G2385R (PD‐G2385R; n = 57), p.R1628P (PD‐R1628P; n = 61), or both (n = 5); patients with iPD (n = 61); and healthy control subjects (HCs; n = 58). Monocyte LRRK2 activity markers (pRab10 Thr73 and pLRRK2 Ser935 ) were analyzed using multiplexed quantitative immunoblotting. Clinical severity was assessed using the International Parkinson and Movement Disorder Society‐Unified Parkinson's Disease Rating Scale, Clinical Impression of Severity Index for PD, and Montreal Cognitive Assessment.

Results

Compared with HCs, pRab10 Thr73 was elevated (indicative of LRRK2 kinase hyperactivation) in PD‐G2385R (~1.2‐fold, P = 0.011) and in double‐variant carriers (~2.8‐fold, P = 0.008), but not in PD‐R1628P or iPD. Inversely correlated with pRab10 Thr73 ( r s = −0.611, P < 0.001), pLRRK2 Ser935 was reduced (indicative of a more active LRRK2 conformation) in all PD subgroups (lowest in double‐variant carriers). All double‐variant carriers, the majority of single‐variant carriers, and one‐third of participants with iPD had pRab10 Thr73 greater than the control median. Higher pRab10 Thr73 correlated with better cognition.

Conclusions

LRRK2 kinase activity is enhanced in patients with PD carrying LRRK2 p.G2385R, with further elevation observed in a small group of double‐variant carriers. Elevated kinase activity in a subset of iPD underscores the relevance of LRRK2 signaling and therapeutics beyond coding variants. The observed interindividual variability indicates additional genetic or environmental modifiers and highlights the need for biochemical stratification beyond genotyping in future LRRK2 trials. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2Parkinson DiseaseHumansFemaleMaleMiddle AgedAgedAsian PeopleHeterozygote

Stichwörter der Autor:innen

BiomarkerKinaseLRRK2Parkinson's diseasePrecision medicine

Substanzen

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, human

Autor:innen und Institutionen

  • Division of Neurology, Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
  • The Mah Pooi Soo & Tan Chin Nam Centre for Parkinson's & Related Disorders, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
  • Department of Physiology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
  • Department of Biomedical Science, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
  • Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, United Kingdom.
  • The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.

ORCID-Profile: Tzi Shin Toh, Lei Cheng Lit, Shen-Yang Lim, Jia Wei Hor, Choey Yee Lew, Anis Nadhirah Khairul Anuar, Yi Wen Tay, Jia Lun Lim, Jannah Zulkefli, Kai Shi Lim, Hans Xing Ding, Shalini Padmanabhan, Azlina Ahmad-Annuar, Dario R Alessi, Esther Sammler, Ai Huey Tan

Förderung

  • Michael J. Fox Foundation for Parkinson's Research

Zitieren

APA

Toh, T. S., Lit, L. C., Lim, S. Y., Hor, J. W., Lew, C. Y., Khairul Anuar, A. N., Tay, Y. W., Black, K., Lim, J. L., Zulkefli, J., Lim, K. S., Ding, H. X., Padmanabhan, S., Ahmad-Annuar, A., Tan, E. K., Alessi, D. R., Sammler, E., & Tan, A. H. (2026). Ex Vivo LRRK2 Activation in Asian G2385R and R1628P Variant Carriers and Idiopathic Parkinson's Disease. Movement Disorders, 41(7), 1750-1761. https://doi.org/10.1002/mds.70314

Vancouver

Toh TS, Lit LC, Lim SY, Hor JW, Lew CY, Khairul Anuar AN, et al. Ex Vivo LRRK2 Activation in Asian G2385R and R1628P Variant Carriers and Idiopathic Parkinson's Disease. Movement Disorders. 2026;41(7):1750-1761. doi:10.1002/mds.70314

BibTeX
@article{Toh2026,
  author = {Toh, Tzi Shin and Lit, Lei Cheng and Lim, Shen-Yang and Hor, Jia Wei and Lew, Choey Yee and Khairul Anuar, Anis Nadhirah and Tay, Yi Wen and Black, Kirsten and Lim, Jia Lun and Zulkefli, Jannah and Lim, Kai Shi and Ding, Hans Xing and Padmanabhan, Shalini and Ahmad-Annuar, Azlina and Tan, Eng King and Alessi, Dario R and Sammler, Esther and Tan, Ai Huey},
  title = {Ex Vivo LRRK2 Activation in Asian G2385R and R1628P Variant Carriers and Idiopathic Parkinson's Disease},
  journal = {Movement Disorders},
  year = {2026},
  volume = {41},
  number = {7},
  pages = {1750--1761},
  doi = {10.1002/mds.70314}
}
Kostenlos starten →